Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
505.00    4.50 (0.90%)
Bid:
505.00
Ask:
505.50
Spread: 0.50 (0.099%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

11 Feb 2022 07:00

RNS Number : 3566B
Tate & Lyle PLC
11 February 2022
 

11 February 2022 - Tate & Lyle PLC

 

 

TRADING STATEMENT

 

Tate & Lyle issues the following trading statement for the three months ended 31 December 2021.

 

Headlines

· Third quarter trading in line with our expectations

· Outlook for total operations (current Tate & Lyle Group) for the year ending 31 March 2022 unchanged, performance of continuing operations (new Tate & Lyle) now expected to be stronger

· Food & Beverage Solutions top-line momentum continues with revenue 19% higher

· New Products performance remains strong with revenue 54% higher

· Positive outcome from the 2022 calendar year pricing round

· Transaction to create two focused businesses on track for completion at the end of March 2022

 

Nick Hampton, Chief Executive said:

"Food & Beverage Solutions delivered another excellent quarter with double-digit revenue growth across all regions and continued high demand for New Products from our innovation pipeline.

 

We enter 2022 in a strong position. Our new business pipeline in Food & Beverage Solutions is healthy and in both our businesses we have renewed 2022 calendar year customer contracts that offset inflation. In addition, the transaction we announced last year to create two focused businesses is progressing well and we remain on track for completion at the end of March.

 

With Tate & Lyle re-positioned as a growth-focused, global food and beverage solutions business serving faster growing markets, we see significant opportunities ahead. Consumer demand for healthier food and drink is accelerating globally and with our leading expertise in sweetening, mouthfeel and fortification, the new Tate & Lyle is well positioned to capture this growth."

 

Continuing operations (New Tate & Lyle)

Strong top-line growth building on positive momentum in the first half.

 

Three months ended 31 December 2021

Volume

Revenue1

Food & Beverage Solutions

+6%

+19%

Sucralose

+7%

+8%

Continuing operations

+18% 

 

1 Growth in constant currency

 

Food & Beverage Solutions

Food & Beverage Solutions revenue growth continued to be strong, increasing by 19% from higher volume, price mix, the benefit of acquisitions and excellent growth from New Products. Looking through the impact of the Covid-19 pandemic and before the impact of reporting changes, compared to the quarter to 31 December 2019, volume was 12% higher and revenue 31% higher.

 

North America and Europe each delivered double-digit revenue growth reflecting good commercial performance and mix management. In Asia, Middle East, Africa and Latin America revenue growth accelerated strongly in the quarter helped by robust growth in China, South-East Asia and Mexico.

 

Sucralose

Revenue was 8% higher reflecting good customer mix and solid demand.

 

Discontinued operations1 (NewCo)

Bulk sweetener volume was broadly in line and industrial starch volume slightly lower than the comparative period. However, as expected, overall performance was significantly weaker due to cost inflation and actions taken to reduce costs in the comparative period to mitigate the impact of the global pandemic.

 

Transaction update

We remain on course to complete the sale of a controlling stake in our Primary Products business in the Americas at the end of March 2022.

 

As previously announced, following completion we intend to return approximately £500 million to ordinary shareholders by way of a special dividend with an associated share consolidation, subject to shareholder approval. We expect to announce the timing of this shortly after completion.

 

Tate & Lyle's results for the year ended 31 March 2022 will be announced on Thursday 9 June 2022.

 

Outlook for year ending 31 March 2022

The outlook for the financial year for total operations (current Tate & Lyle) remains unchanged with the performance of continuing operations expected to be stronger and discontinued operations weaker, as set out below.

 

Continuing operations (new Tate & Lyle)

· Growth in adjusted profit before tax in constant currency is now expected to be in the low double-digit percent range

 

Total operations (current Tate & Lyle Group)

· Change in adjusted diluted earnings per share in constant currency to be mid single-digits percent lower due to the performance of discontinued operations and cost inflation.

 

-------------------------------------------------------------------------------

1 The discontinued business represents the disposed Primary Products business in North America and Latin America and its interests in the Almidones Mexicanos S.A de C.V and DuPont Tate & Lyle Bio-Products Company, LLC joint ventures (also referred to in this statement as NewCo).

 

END

 

A conference call will be held today at 10.00am GMT hosted by Nick Hampton, Chief Executive. Participants are requested to dial in at least 10 minutes before the start of the call. Dial in details are as follows:

 

Standard International Access: +44 (0)3305 510 202

Password: 5507290#

 

A replay of this call will be available after the end of the live call for 14 days until 24 February 2022.

Replay number: +44 (0)20 8196 1480

Replay access PIN: 5507290#

 

 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

 

Nick Hasell (FTI Consulting), Media Relations

Mobile: +44 (0)7825 523 383

 

About Tate & Lyle:

Tate & Lyle PLC is a leading global provider of food and beverage ingredients and solutions. Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

 

Through our expertise in sweetening, mouthfeel and fibre fortification, our Food & Beverage Solutions business develops solutions which reduce sugar, calories and fat, add fibre, and provide texture and stability in categories including beverages, dairy, bakery, soups, sauces and dressings. Our Primary Products business produces nutritive sweeteners, industrial starches used in paper and packaging, acidulants and products used for animal nutrition.

 

We have around 4,200 employees working in more than 60 locations across 30 countries. Tate & Lyle's purpose is Improving Lives for Generations and through our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2021, Tate & Lyle sales totalled £2.8 billion. For more information, please visit http://www.tateandlyle.com or follow Tate & Lyle on Twitter, Linkedin or Facebook.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBKKBBOBKDABD
Date   Source Headline
27th Mar 20262:00 pmRNSHolding(s) in Company
13th Mar 20264:00 pmRNSHolding(s) in Company
2nd Mar 20262:00 pmRNSHolding(s) in Company
26th Feb 20267:00 amRNSTrading Statement
23rd Feb 202610:00 amRNSHolding(s) in Company
17th Feb 202612:00 pmRNSHolding(s) in Company
21st Jan 20267:00 amRNSDirectorate change
15th Jan 20269:00 amRNSHolding(s) in Company
12th Jan 202610:00 amRNSHolding(s) in Company
7th Jan 20264:30 pmRNSDirector/PDMR Shareholding
7th Jan 20262:30 pmRNSBlock listing Interim Review
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
18th Dec 20252:00 pmRNSDirector/PDMR Shareholding
11th Dec 202512:18 pmRNSDirector/PDMR Shareholding
9th Dec 20259:00 amRNSHolding(s) in Company
27th Nov 202510:00 amRNSDirector/PDMR Shareholding
11th Nov 20254:30 pmRNSDirector/PDMR Shareholding
10th Nov 20252:40 pmRNSDirector Declaration
6th Nov 20257:00 amRNSHalf-year Financial Report
5th Nov 20252:15 pmRNSHolding(s) in Company
3rd Nov 20255:00 pmRNSHolding(s) in Company
29th Oct 20252:00 pmRNSHolding(s) in Company
23rd Oct 20254:15 pmRNSHolding(s) in Company
21st Oct 20253:30 pmRNSHolding(s) in Company
16th Oct 202512:00 pmRNSHolding(s) in Company
8th Oct 202512:00 pmRNSHolding(s) in Company
6th Oct 20254:30 pmRNSDirector/PDMR Shareholding
6th Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 20254:00 pmRNSDirector/PDMR Shareholding
3rd Oct 202510:00 amRNSDirector/PDMR Shareholding
1st Oct 20257:00 amRNSPre-close statement
2nd Sep 20258:00 amRNSTotal Voting Rights
11th Aug 20251:00 pmRNSDirector/PDMR Shareholding
5th Aug 20257:00 amRNSDirector/PDMR Shareholding
1st Aug 202511:00 amRNSTotal Voting Rights
24th Jul 20252:30 pmRNSResult of Annual General Meeting 2025
15th Jul 20251:00 pmRNSDirector/PDMR Shareholding
1st Jul 20253:30 pmRNSBlock listing Interim Review
1st Jul 20257:00 amRNSTate & Lyle Capital Markets Event
13th Jun 20253:00 pmRNSHolding(s) in Company
11th Jun 20254:30 pmRNSDirector/PDMR Shareholding
5th Jun 20252:30 pmRNSAnnual Financial Report and Notice of Meeting 2025
5th Jun 20252:00 pmRNSDirector/PDMR Shareholding
2nd Jun 202512:30 pmRNSTotal Voting Rights
28th May 202512:00 pmRNSDirector/PDMR Shareholding
27th May 202512:00 pmRNSDirector/PDMR Shareholding
23rd May 202510:00 amRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSFinal Results
14th May 20259:00 amRNSHolding(s) in Company
1st May 20253:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.